Private company

Monogram Technologies Inc.

Monogram Technologies Inc. is an American surgical and medical instruments and apparatus company.1 It is headquartered in Austin, Texas.1

Last updated Oct 20, 2026.

Overview

  • IndustrySurgical & Medical Instruments & Apparatus1
  • HeadquartersAustin, Texas1
  • Incorporated inDE2
  • Business address3913 Todd Lane, Suite 307, Austin, Tx 787442
  • Filer category, Emerging growth company2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

-4731.0%Operating margin3
-3765.8%Net margin3
-102.6%Return on equity3

Where the money goes

Where each dollar of revenue went, fiscal 2023

  • Research and development100¢$10.6M

Out of $365.0K in revenue.3 The company lost money this year.

Financial statements

Operating income43-$17.3M in 2023+63% since 2022
-$20.0M-$15.0M-$10.0M-$5.0M02022: -$10.6M-$10.6M20222023: -$17.3M-$17.3M2023+63%
Net income43-$13.7M in 2023+0% since 2022
-$15.0M-$10.0M-$5.0M02022: -$13.7M-$13.7M20222023: -$13.7M-$13.7M2023+0%
Fiscal year202120222023
Revenue$365.0K3
Research and development$5.4M4$10.6M3
Operating expenses$10.6M4$17.6M3
Operating income-$10.6M4-$17.3M3
Income before tax-$13.7M4-$13.7M3
Income tax$04$03
Net income-$13.7M4-$13.7M3
Earnings per share-$1.424-$0.613
Earnings per share (diluted)-$1.424-$0.613
Shares (weighted, basic)9.7M shares422.4M shares3
Shares (weighted, diluted)9.7M shares422.4M shares3

Compare Monogram Technologies Inc. with another company

Corporate structure

Monogram Technologies Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Monogram Technologies Inc.

  • School Of Medicine At Mount Sinai Icahn Filed SCHEDULE 13G on Monogram Technologies Inc., latest Jul 18, 2025
  • Monogram Technologies Inc. Austin, Texas

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Monogram Technologies Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$1.7M3 Dec 31, 2024$1.7M3 Dec 31, 2023+5.1%
Accumulated depreciation$927.0K3 Dec 31, 2024$707.0K3 Dec 31, 2023+31.1%
Property and equipment, net$810.0K3 Dec 31, 2024$945.0K3 Dec 31, 2023−14.3%
Operating-lease assets (leased space)$338.0K3 Dec 31, 2024$467.0K3 Dec 31, 2023−27.6%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$15.7M3 Dec 31, 2024$13.6M3 Dec 31, 2023+15.2%

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)$339.0K3 Dec 31, 2024$549.0K3 Dec 31, 2023−38.3%
Accumulated amortization$786.0K3 Dec 31, 2024$576.0K3 Dec 31, 2023+36.5%

Properties, in its own words

The Company leases property that serves as its headquarters at 3913 Todd Lane, Suite 307, Austin, TX 78744. The Company has installed a 352 square foot cadaver lab at this Austin facility to support its research and development initiatives. The cadaver lab has a dedicated surgical robot and navigation system that engineers use to support testing and product development.

Item 2 of the 10-K filed Mar 12, 2025.7

Leadership

Who has led Monogram Technologies Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Benjamin Sexson2023–now

Chief financial officer

  1. Noel Knape2023–now
2025
Board members and other officers (9)

Former names

  • MONOGRAM ORTHOPAEDICS INCMar 13, 2019 to May 17, 20242

Timeline

  1. Oct 7, 20258-K Completed an acquisition or sale; Listing notice or transfer; Change to shareholders' rights18
  2. Sep 30, 20258-K Shareholder vote19
  3. Sep 5, 20258-K Other events20
  4. Aug 29, 20258-K Regulation FD disclosure21
  5. Aug 28, 20258-K Entered a material agreement22
  6. Jul 31, 20258-K Regulation FD disclosure23
  7. Jul 30, 20258-K Regulation FD disclosure24
  8. Jul 29, 20258-K Regulation FD disclosure25
  9. Jul 28, 20258-K Regulation FD disclosure26
  10. Jul 14, 20258-K Entered a material agreement; Regulation FD disclosure27
  11. Jul 14, 20258-K Ended a material agreement; Unregistered sale of shares; Bylaws or fiscal year changed28
  12. Jul 8, 20258-K Change to shareholders' rights; Other events29
  13. May 17, 2023New chief executive Benjamin Sexson becomes CEO8

Calendar

When it reported results

  1. Mar 13, 2025Reported quarterly or annual results30
  2. Mar 12, 2025Reported quarterly or annual results31
  3. Nov 14, 2024Reported quarterly or annual results32
  4. May 14, 2024Reported quarterly or annual results33
  5. Mar 15, 2024Reported quarterly or annual results34

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

152 filings to the SEC since October 2021: 2 annual reports, 8 quarterly reports, 43 major events, 24 insider forms, 1 large holders, 74 other. The latest 20:

  1. Nov 19, 2025EFFECT EDGAR
  2. Nov 19, 2025EFFECT EDGAR
  3. Oct 21, 202515-12G EDGAR
  4. Oct 14, 20254 OWNERSHIP DOCUMENT EDGAR
  5. Oct 14, 20254 OWNERSHIP DOCUMENT EDGAR
  6. Oct 14, 20253 OWNERSHIP DOCUMENT EDGAR
  7. Oct 7, 2025S-8 POS EDGAR
  8. Oct 7, 2025POS AM EDGAR
  9. Oct 7, 2025POS AM EDGAR
  10. Oct 7, 20254 OWNERSHIP DOCUMENT EDGAR
  11. Oct 7, 20254 OWNERSHIP DOCUMENT EDGAR
  12. Oct 7, 20254 OWNERSHIP DOCUMENT EDGAR
  13. Oct 7, 20254 OWNERSHIP DOCUMENT EDGAR
  14. Oct 7, 20254 OWNERSHIP DOCUMENT EDGAR
  15. Oct 7, 20254 OWNERSHIP DOCUMENT EDGAR
  16. Oct 7, 20258-K EDGAR
  17. Sep 30, 20258-K EDGAR
  18. Sep 30, 20254 OWNERSHIP DOCUMENT EDGAR
  19. Sep 30, 20254 OWNERSHIP DOCUMENT EDGAR
  20. Sep 30, 20254 OWNERSHIP DOCUMENT EDGAR

The 152 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

  • School Of Medicine At Mount Sinai IcahnSCHEDULE 13G, 1 filing Jul 18, 202535

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2023Noel KnapeChief Financial Officer56$160.4K$465.4K36
2023Benjamin Sexson ChiefExecutive Officer$250.0K$375.0K36
2023Kamran ShamaeiChief Technology Officer41$275.0K$347.0K36
2022Kamran ShamaeiChief Technology Officer41$235.0K$2.2M36
2022Benjamin Sexson ChiefExecutive Officer$250.0K$1.6M36

SEC filer profile

How Monogram Technologies Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARMonogram Technologies Inc.1
  • CIK0001769759
  • Employer ID (EIN)81-23495407
  • Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; not a shell company7
  • Incorporated inDelaware7
  • Fiscal year endsDecember 311
  • Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus1
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
  • Business address3913 Todd Lane, Suite 307, Austin, TX 787441
  • Phone512-399-26561
  • Shares outstanding40,632,367 as of Aug 11, 20256
  • Public float$57.1M as of Mar 11, 20257
  • AuditorFruci & Associates II, PLLC, Spokane, Washington PCAOB ID 5525; no auditor attestation of internal control over financial reporting7
  • On EDGAR sinceMar 13, 20191
  • Filings200 in all: 8-K (42), CORRESP (18), 4 (16), 1-A/A (15), UPLOAD (15), 10-Q (8), 3 (8), 253G2 (7)1
    All 42 form types

    424B5 (7), DEFA14A (7), EFFECT (5), 1-A (4), 1-K (4), 1-SA (4), 424B3 (4), QUALIF (4), POS AM (3), 10-K (2), DEF 14A (2), NT 10-Q (2), PRE 14A (2), 1-A POS (1), 1-A-W (1), 15-12G (1), 25-NSE (1), 425 (1), 8-A12B (1), 8-K/A (1), C (1), C-AR (1), CERT (1), DEFM14A (1), PREM14A (1), PRER14A (1), S-1 (1), S-1/A (1), S-3 (1), S-8 (1), S-8 POS (1), SC 13D (1), SCHEDULE 13D (1), SCHEDULE 13G (1)

  • Latest filingsAnnual report (10-K) Mar 12, 2025
    Quarterly report (10-Q) Aug 15, 2025
    Proxy statement (DEF 14A) Nov 8, 2024
    Latest 8-K (8-K) Oct 7, 2025

Securities registered for trading

ClassSymbolExchange
Common Stock, $0.001 par value per shareMGRMNasdaq

From the cover page of the 10-K filed Mar 12, 2025 (Section 12(b) of the Exchange Act).7

Risk factors and legal proceedings

The risks Monogram Technologies Inc. names in Item 1A of its 10-K filed Mar 12, 2025: 51 risks under these headings, as written.7

  • Risks Related to Our Company
  • We have a limited operating history upon which you can evaluate our performance. Accordingly, our prospects must be considered in light of the risks that any new company encounters.
  • We have no products approved for commercial sale, have generated minimal revenues related to OUS opportunities and may never achieve significant revenues or profitability, which could cause us to cease operations.
  • We will need to outsource and rely on third parties for various aspects relating to the development, manufacture, distribution, and sale and marketing of our products as well as in connection with assisting us in the preparation and filing of our FDA 510(k) premarket clearance submissions(s).
  • Our technology is not yet fully developed, and there is no guarantee that we will successfully develop our technology.
  • We are subject to substantial governmental regulation relating to the manufacturing, labeling, and marketing of our developmental products, and will continue to be for the lifetime of our Company.
  • We are subject to federal and state healthcare regulations and laws relating to anti-bribery and anti-corruption, and non-compliance with such laws could lead to significant penalties.
  • Government regulations and other legal requirements affecting our Company are subject to change. Such change could have a material adverse effect on our business.
  • Changes in laws, regulations, and policies and the related interpretations and enforcement practices may significantly affect our cost of doing business as we endeavor to maintain compliance with such new policies and laws.
  • We have not yet obtained clearance of our products by the U. S. Food and Drug Administration, or FDA, which is critical to our business plan.
  • If the FDA requires us to provide clinical data to obtain clearance for our product candidates, it could pose a significant obstacle to business and plan of operations.
  • We can provide no assurance that our medical device product candidates will obtain regulatory clearance or that the results of clinical studies, if required, will be favorable.
The other 40 risks
  • Recent Downsizing of FDA Personnel Reviewing Medical Device Applications May Adversely Affect Our Regulatory Approval Timeline and Create Uncertainty in the Approval Process.
  • There may be delays of our clinical trial by international regulatory agencies.
  • Assuming our surgical robot or other product candidates receive 510(k) premarket clearance, our products will still be subject to recalls, which could harm our reputation, business operations and financial results.
  • We anticipate initially sustaining operating losses.
  • We may need to raise substantial additional capital in the future to fund our operations and we may be unable to raise such funds when needed and on acceptable terms, which could have a materially adverse effect on our business.
  • We may experience property theft and inventory control issues.
  • Our products may not gain market acceptance among hospitals, surgeons, physicians, patients, healthcare payors, and the medical community.
  • We could be adversely affected by product liability, personal injury or other health and safety issues.
  • If third-party payors fail to provide appropriate levels of reimbursement for the use of our products, our revenues could be adversely affected.
  • We face risks related to our license agreement with the Icahn School of Medicine at Mount Sinai.
  • We operate in a highly competitive industry that is dominated by several very large, well-capitalized market leaders and is continuously evolving. New entrants to the market, existing competitor actions, or other changes in market dynamics could adversely impact us.
  • Successful infringement claims against us could result in significant monetary liability or prevent us from selling some of our products.
  • The Company’s success depends on the experience and skill of the board of directors, its executive officers and key employees.
  • Our failure to attract and retain highly qualified personnel in the future could harm our business.
  • Certain of our non-executive employees rely on work visas in order to work at our Company, and as a result, we may experience disruptions resulting from visa issues encountered by members of our staff.
  • We may spend material amounts on marketing that may not be effective.
  • We have no manufacturing experience, and we rely entirely on third-party manufacturers and service providers to produce our medical device product candidates.
  • Our products may be more expensive to produce than we estimate.
  • Our technologies are highly complex, and development budget estimates may not be accurately or sufficiently forecasted.
  • Our products may require more technical complexity than anticipated and our engineers may not be able to overcome these technical challenges.
  • We may not gain acceptance by group purchasing organizations or other purchasing entities.
  • We do not currently have the sales and marketing personnel necessary to sell products, and the failure to hire and retain such staff, or retain a third-party with sales and marketing personnel to fulfill that function, could have a materially adverse effect on our business.
  • We may use independent distributors to represent our products.
  • Our products require a level of accuracy that we may never be able to achieve.
  • Our products may not provide a clinical benefit.
  • Our use of artificial intelligence (AI) and machine learning (ML) technologies is subject to significant regulatory oversight, and changes in regulations or guidance could impact our ability to develop and commercialize AI-driven solutions.
  • The effectiveness and reliability of our AI-driven technologies depend on data quality, and limitations in data diversity or accuracy could impact performance.
  • If our AI and ML models do not perform as intended, we could be exposed to increased liability risks, including product liability claims and regulatory enforcement actions.
  • Our AI-driven applications depend on evolving computing infrastructure and may require additional resources as we scale.
  • If we fail to clearly communicate the actual capabilities and limitations of our AI technologies, we may face regulatory scrutiny, reputational harm, and potential liability.
  • We may have to reduce our headcount if we are unable to raise sufficient funds.
  • Our assets may become pledged as collateral to a lender.
  • We may fail to meet the Sarbanes-Oxley regulations and may lack the financial controls and safeguards required of public companies.
  • Acquisition opportunities may present themselves do not achieve the positive results anticipated by our management.
  • Risks Related to Ownership of Our Common Stock
  • The market price of our Common Stock has been and will likely continue to be volatile, and you could lose all or part of your investment.
  • Raising additional capital may cause significant dilution to our stockholders and adversely affect the market price for our Common Stock.
  • If securities or industry analysts do not publish research or publish unfavorable or inaccurate research about our business, the market price and trading volume of our Common Stock could decline.
  • Provisions in our Sixth Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws and Delaware law might discourage, delay, or prevent a change in control of our company or changes in our management and, therefore, depress the market prices of our Common Stock.
  • Our Sixth Amended and Restated Certificate of Incorporation provides that the Court of Chancery of the State of Delaware and the federal district courts of the United States of America will be the exclusive forums for substantially all disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.
  • Anti-Takeover Effects of Our Sixth Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws could impair a takeover attempt.

Legal proceedings

From time to time, the Company may be involved in a variety of legal matters that arise in the normal course of business. The Company is not currently involved in any material litigation, and its management is not aware of any pending or threatened material legal actions relating to its intellectual property, conduct of its business activities, or otherwise.

Following our listing on Nasdaq, a former investor filed suit against the Company and its Transfer Agent in July 2023 in New York County Supreme Court. Both the Company and our Transfer Agent believe the claim is without merit and are seeking dismissal of the action, most recently filing a Reply Memorandum of Law in Support of Renewed Motion to Dismiss on February 13, 2024. There have been no updates since this filing.

See “Risk Factors” for a summary of risks our Company may face in relation to litigation against our Company.

The opening of Item 3, Legal Proceedings.7

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
    SEC EDGAROther events
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36